Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Publikation

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.

Wissenschaftlicher Artikel/Review - 29.04.2024

Burmester Gerd R, Stigler Jayne, Rubbert-Roth Andrea, Tanaka Yoshiya, Azevedo Valderilio F, Coombs Derek, Lagunes Ivan, Lippe Ralph, Wung Peter, Gensler Lianne S

Zitation

Burmester G, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo V, Coombs D, Lagunes I, Lippe R, Wung P, Gensler L. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther 2024; 11:737-753.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Rheumatol Ther 2024; 11

Veröffentlichungsdatum

29.04.2024

ISSN (Druck)

2198-6576

Seiten

737-753

Kurzbeschreibung/Zielsetzung

This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) (including pooled axial spondyloarthritis [axSpA]).